Total Payments
$6,502
2024 Payments
$578.86
Companies
31
Transactions
281
Medicare Patients
4,441
Medicare Billing
$411,846
Payment Breakdown by Category
Food & Beverage$6,497 (99.9%)
Education$5.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,497 | 280 | 99.9% |
| Education | $5.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,442 | 60 | $0 (2024) |
| Amgen Inc. | $903.76 | 36 | $0 (2024) |
| Novo Nordisk Inc | $586.67 | 29 | $0 (2024) |
| Lilly USA, LLC | $504.88 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $450.51 | 19 | $0 (2024) |
| PFIZER INC. | $374.37 | 18 | $0 (2024) |
| Allergan, Inc. | $279.35 | 16 | $0 (2020) |
| GlaxoSmithKline, LLC. | $258.68 | 12 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $168.83 | 4 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $156.14 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $578.86 | 23 | ABBVIE INC. ($245.07) |
| 2023 | $1,078 | 42 | AbbVie Inc. ($357.11) |
| 2022 | $517.02 | 24 | ABBVIE INC. ($199.51) |
| 2021 | $974.34 | 45 | AbbVie Inc. ($372.34) |
| 2020 | $720.08 | 41 | Amgen Inc. ($158.09) |
| 2019 | $1,029 | 38 | Novo Nordisk Inc ($165.62) |
| 2018 | $948.51 | 36 | Amgen Inc. ($204.03) |
| 2017 | $656.92 | 32 | AstraZeneca Pharmaceuticals LP ($197.32) |
All Payment Transactions
281 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological), Winlevi | Food and Beverage | In-kind items and services | $38.35 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Bone Health | ||||||
| 11/19/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.24 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Obesity | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Respiratory | ||||||
| 09/10/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Inflammation | ||||||
| 08/21/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: Diabetes | ||||||
| 08/13/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Bone Health | ||||||
| 07/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.08 | General |
| Category: NEUROSCIENCE | ||||||
| 06/26/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.43 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: PAIN | ||||||
| 06/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.06 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2024 | ABBVIE INC. | CREON (Drug), VIBERZI, LINZESS | Food and Beverage | In-kind items and services | $32.90 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/07/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $27.41 | General |
| Category: Obesity | ||||||
| 01/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Cardiology | ||||||
| 01/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.53 | General |
| Category: NEUROSCIENCE | ||||||
| 01/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: NEUROSCIENCE | ||||||
| 01/15/2024 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $63.96 | General |
| Category: NEUROLOGY | ||||||
| 01/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.55 | General |
| Category: NEUROSCIENCE | ||||||
| 01/07/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2023 | Catalyst Pharmaceuticals, Inc. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $42.64 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 729 | 1,287 | $207,058 | $85,434 |
| 2022 | 28 | 1,530 | 2,866 | $429,227 | $128,926 |
| 2021 | 25 | 1,124 | 2,101 | $300,245 | $109,198 |
| 2020 | 23 | 1,058 | 1,948 | $224,106 | $88,288 |
Total Patients
4,441
Total Services
8,202
Medicare Billing
$411,846
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 230 | 511 | $111,372 | $43,217 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 199 | $30,638 | $12,703 | 41.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 85 | $25,762 | $11,584 | 45.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 53 | 53 | $11,768 | $7,318 | 62.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 33 | 33 | $3,828 | $2,426 | 63.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,236 | $2,114 | 33.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 20 | 27 | $3,785 | $1,277 | 33.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 38 | 38 | $1,791 | $1,216 | 67.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 11 | 17 | $2,724 | $940.78 | 34.5% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 16 | 19 | $1,981 | $712.77 | 36.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 45 | $1,508 | $528.46 | 35.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 41 | 45 | $2,450 | $517.65 | 21.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 16 | 63 | $1,094 | $358.41 | 32.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 11 | 12 | $879.60 | $205.91 | 23.4% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 11 | 12 | $387.69 | $110.70 | 28.6% |
| 81002 | Urinalysis, manual test | Office | 2023 | 24 | 29 | $455.59 | $96.34 | 21.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 16 | 72 | $226.08 | $61.65 | 27.3% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2023 | 11 | 11 | $172.81 | $47.19 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 340 | 870 | $187,837 | $45,800 | 24.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 239 | 483 | $74,363 | $22,849 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 76 | 76 | $27,471 | $9,911 | 36.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 31 | 33 | $13,284 | $9,089 | 68.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 122 | 122 | $25,935 | $7,098 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 74 | 105 | $31,360 | $6,904 | 22.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 49 | 52 | $5,442 | $3,360 | 61.7% |
About Dr. David Arthurs, DO
Dr. David Arthurs, DO is a Family Medicine healthcare provider based in Kealakekua, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932153111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Arthurs, DO has received a total of $6,502 in payments from pharmaceutical and medical device companies, with $578.86 received in 2024. These payments were reported across 281 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,497).
As a Medicare-enrolled provider, Arthurs has provided services to 4,441 Medicare beneficiaries, totaling 8,202 services with total Medicare billing of $411,846. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Kealakekua, HI
- Active Since 05/20/2006
- Last Updated 07/09/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1932153111
Products in Payments
- UBRELVY (Drug) $634.67
- Ozempic (Drug) $354.95
- Repatha (Biological) $350.15
- VRAYLAR (Drug) $302.20
- Aimovig (Biological) $289.22
- TRULICITY (Drug) $247.84
- QULIPTA (Drug) $232.12
- FARXIGA (Drug) $200.54
- MOUNJARO (Drug) $165.85
- BYDUREON (Drug) $158.12
- EVENITY (Biological) $150.20
- JARDIANCE (Drug) $140.93
- Tymlos (Biological) $128.04
- PRALUENT (Drug) $127.87
- ANORO (Drug) $120.98
- XARELTO (Drug) $115.86
- FIRDAPSE (Drug) $106.60
- Androgel (Drug) $105.67
- BOTOX (Biological) $99.17
- NURTEC ODT (Drug) $97.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.